Toward a PSMA PET–mpMRI pathway for biopsy decision-making in men with suspected prostate cancer: interim results from the prospective BIOPSTAGE trial
Integrating semiquantitative PSMA PET with mpMRI improves lesion-level specificity and was associated with a theoretical reduction of approximately two-thirds in the number of targeted biopsy cores, while maintaining high sensitivity. While PSMA PET enhances risk stratification, mpMRI remains essential-particularly for detecting small or PSMA-negative tumors. These interim findings support feasibility of a dual-imaging biopsy triage strategy, pending validation in the full BIOPSTAGE cohort and future multicenter trials.
Authors
- Irene Marini (ORCID: https://orcid.org/0009-0002-6186-688X)
- Roberta Gunelli
- Valentina Di Iorio (ORCID: https://orcid.org/0000-0002-5380-6185)
- Eugenia Fragalà (ORCID: https://orcid.org/0000-0002-4779-2012)
- Lorenzo Fantini
- F. Matteucci
- Flavia Foca (ORCID: https://orcid.org/0000-0002-5529-4769)
- M. Monti
- Monica Celli (ORCID: https://orcid.org/0000-0002-0338-800X)
- Fabio Ferroni
- Domenico Barone
- Paola Caroli
- Matteo Costantini
Institutions
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Ospedale G.B. Morgagni - L.Pierantoni (IT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.3389/fonc.2025.1720861
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Associazione Italiana per la Ricerca sul Cancro